Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Palak Trivedi

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Journal of Hepatology|May 23, 2017
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitisPeter Fickert, Gideon M Hirschfield, Gerald Denk, et al.
JCI Insight|June 22, 2023
CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitisRaanan Greenman, Michal Segal-Salto, Neta Barashi, et al.
Hepatology (Baltimore, Md.)|March 20, 2024
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?David E J Jones, Ulrich Beuers, Alan Bonder, et al.
BMJ Open|March 11, 2026
Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acidSarah Dunn, Lysbeth Evans, Ciara Kennedy, et al.
Alimentary Pharmacology & Therapeutics|March 25, 2021
Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitisPierre-Antoine Soret, Laurent Lam, Fabrice Carrat, et al.
JHEP Reports : Innovation in Hepatology|May 13, 2026
Quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitisTim E Middelburg, Laura Cristoferi, Willemijn Ponsioen, et al.
Gastroenterology|October 9, 2018
Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient SurvivalAldo J Montano-Loza, Bettina E Hansen, Christophe Corpechot, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
American Journal of Human Genetics|April 9, 2022
Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutationsJohn Devane, Elisabeth Ott, Eric G Olinger, et al.
Journal of Hepatology|April 11, 2020
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitisChristophe Corpechot, Olivier Chazouillères, Pierre Belnou, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Journal of Hepatology|May 23, 2017
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitisPeter Fickert, Gideon M Hirschfield, Gerald Denk, et al.
JCI Insight|June 22, 2023
CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitisRaanan Greenman, Michal Segal-Salto, Neta Barashi, et al.
Hepatology (Baltimore, Md.)|March 20, 2024
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?David E J Jones, Ulrich Beuers, Alan Bonder, et al.
BMJ Open|March 11, 2026
Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acidSarah Dunn, Lysbeth Evans, Ciara Kennedy, et al.
Alimentary Pharmacology & Therapeutics|March 25, 2021
Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitisPierre-Antoine Soret, Laurent Lam, Fabrice Carrat, et al.
JHEP Reports : Innovation in Hepatology|May 13, 2026
Quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitisTim E Middelburg, Laura Cristoferi, Willemijn Ponsioen, et al.
Gastroenterology|October 9, 2018
Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient SurvivalAldo J Montano-Loza, Bettina E Hansen, Christophe Corpechot, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
American Journal of Human Genetics|April 9, 2022
Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutationsJohn Devane, Elisabeth Ott, Eric G Olinger, et al.
Journal of Hepatology|April 11, 2020
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitisChristophe Corpechot, Olivier Chazouillères, Pierre Belnou, et al.
Pageof 3